Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Enliven Therapeutics Inc., 3 years.
Enliven Therapeutics Inc.
Director
Agios Pharmaceuticals Inc.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Agios Pharmaceuticals Inc. June 18, 202687.1%
-
Enliven Therapeutics Inc. June 24, 202598.8%
-
Agios Pharmaceuticals Inc. June 13, 202396.1%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 18, 2026 | Agios Pharmaceuticals Inc. | Option exercise | +2,816 | — | — |
| Aug 11, 2025 | Agios Pharmaceuticals Inc. | Option exercise | +2,302 | — | — |
| Jun 20, 2025 | Agios Pharmaceuticals Inc. | Option exercise | +2,120 | — | — |
| Nov 8, 2024 | Agios Pharmaceuticals Inc. | Option exercise | +10,000 | $25.99 | $259,900 |
| Nov 8, 2024 | Agios Pharmaceuticals Inc. | Open-market sale | −3,571 | $57.24 | $204,404 |
| Nov 8, 2024 | Agios Pharmaceuticals Inc. | Open-market sale | −4,929 | $58.57 | $288,692 |
| Nov 8, 2024 | Agios Pharmaceuticals Inc. | Open-market sale | −1,500 | $59.21 | $88,815 |
| Nov 7, 2024 | Agios Pharmaceuticals Inc. | Option exercise | +10,000 | $25.99 | $259,900 |
| Nov 7, 2024 | Agios Pharmaceuticals Inc. | Open-market sale | −8,132 | $53.32 | $433,598 |
| Nov 7, 2024 | Agios Pharmaceuticals Inc. | Open-market sale | −1,868 | $54.41 | $101,638 |
| Oct 8, 2024 | Enliven Therapeutics Inc. | Option exercise | +6,314 | $19.68 | $124,260 |
| Oct 8, 2024 | Enliven Therapeutics Inc. | Option exercise | +4,106 | $5.52 | $22,665 |
| Oct 8, 2024 | Enliven Therapeutics Inc. | Open-market sale | −10,420 | $28.17 | $293,531 |
| Aug 11, 2024 | Agios Pharmaceuticals Inc. | Option exercise | +2,302 | — | — |
| Jun 13, 2024 | Agios Pharmaceuticals Inc. | Option exercise | +3,388 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.